Table 5.
AMP in clinical development (adapted from Koo and Seo, 2019).
| AMP | Source | Targetc | Phase | Company | Administrationd |
|---|---|---|---|---|---|
| EA-230 | hCG derivative | Sepsis and renal failure protection | II | Exponential biotherapies | Iv |
| CZEN-002 | α-MSH derivative | Anti-fungal | IIb | Zengen | Top |
| D2A21 | Synthetic | Burn wound infections | III | Demegen | Top |
| XMP-629 | BPI derivative | Impetigo and acne rosacea | IIIb | Xoma Ltd. | Top |
| Neuprex(rBPI21) | BPR derivative | Peadiatric meningococcemia | IIIb | Xoma Ltd. | iv |
| Delmitide(RDP58) | HLA class I derivative | Inflammatory bowel disease | IIa | Genzyme | Top |
| Ghrelin | Endogenous HDP | Chronic respiratory failure | IIa | University of Miyazaki; Papworth Hospital | iv |
| hLF1-11 | Lactoferricin derivative | MRSA, K. pneumoniae, L. monocytogenes | I/II | AM-Pharma | iv |
| C16G2 | Synthetic | Tooth decay by Streptococcus mutans | II | C3 Jian Inc. | Mouthwash |
| SGX942(Dusquetide) | Synthetic | Oral mucositis | III | Soligenix | Oral rinse |
| DPK-060 | Kininogen derivative | Acute external otitis | II | ProMore pharma | Ear drops |
| PXL01 | Lactoferrin analogue | Postsurgical adhesions | III | ProMore pharma | Top |
| PAC113 | Histatin 5 analogue | Oral candidiasis | IIa | Pacgen biopharmaceuticals | Mouth rinse |
| POL7080 | Protegrin analogue | P. aeruginosa, K. pneumoniae | III | Polyphor Ltd. | iv |
| LTX-109 (Lytixar) | Synthetic | G+, MRSA skin infection; impetigo | IIa | Lytix biopharma | Top |
| OP-145 | LL-37 derivative | Chronic middle ear infection | IIa | Dr. Reddy's research | Ear drops |
| LL-37 | Human cathelicidin | Leg ulcer | IIb | ProMore pharma | Top |
| Novexatin (NP213) | Cyclic cationic peptide | Fungal nail infection | IIa | NovaBiotics Ltd. | Top |
| p2TA (AB103) | Synthetic | Necrotizing soft tissue infections | III | Atox Bio Ltd. | iv |
| Iseganan (IB-367) | Protegrin analogue | Pneumonia, stomatitis | IIIb | IntraBiotics pharmaceuticals | Top |
| Pexiganan (MSI-78) | Magainin analogue | Diabetic foot ulcers | IIIb | Dipexium pharmaceuticals | Top |
| Omiganan (CLS001) | Indolicidin derivative | Rosacea | III | Cutanea life sciences | Top |
a
Clinical trial completed.
b
Clinical trial discontinued.
c
Target microorgansim: G+ - Gram positive; MRSA – methicillin-resistant S. aureus.
d
Route of administration: top - topical; iv – intravenous.